©2022 Stanford Medicine
Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal
Not Recruiting
Trial ID: NCT00661674
Purpose
Opioid medications are commonly used for pain relief. When given over time, physical
dependence can occur. This results in unpleasant side effects--such as agitation and
nausea--if opioid medications are suddenly stopped. We are interested in knowing if a
medication named Ondansetron can help ease or prevent symptoms associated with opioid
withdrawal. We are also interested in knowing if a similar (but more potent FDA-approved
drug, palonosetron) can more effectively treat withdrawal symptoms with or without
combination with an antihistamine called hydroxyzine (vistaril).
Official Title
Examination of Palonosetron and Hydroxyzine Pre-treatment as a Possible Method to Reduce the Objective Signs of Experimentally-induced Acute Opioid Withdrawal in Humans: a Double-blind, Randomized, Placebo-controlled Crossover Study
Stanford Investigator(s)
Lawrence Chu, MD, MS
Professor of Anesthesiology, Perioperative and Pain Medicine
Eligibility
Inclusion Criteria:
- Healthy males
- Ages 18-35
- No allergies to morphine or palonosetron
- No history of addiction or substance abuse
Exclusion Criteria:
- Female
- Younger than 18 or older than 35
- History of substance abuse
- Raynaud's disease or coronary artery disease
- Allergies to morphine or palonosetron
Intervention(s):
drug: palonosetron
drug: hydroxyzine
other: Placebo
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305